SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer. 2004; 100: 228-237.
  • 2
    Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006; 106: 2258-2266.
  • 3
    Lyman GH, Kuderer NM. Epidemiology of febrile neutropenia. Support Cancer Ther. 2003; 1: 23-35.
  • 4
    Crawford J, Dale DC, Kuderer NM, et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw. 2008; 6: 109-118.
  • 5
    Lyman GH, Delgado DJ. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma. Cancer. 2003; 98: 2402-2409.
  • 6
    Lyman GH, Morrison VA, Dale DC, et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma. 2003; 44: 2069-2076.
  • 7
    Lyman GH, Lyman CH, Agboola O. Risk models for predicting chemotherapy-induced neutropenia. Oncologist. 2005; 10: 427-437.
  • 8
    Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993; 328: 1323-1332.
  • 9
    Barron RL. Pathophysiology of septic shock and implications for therapy. Clin Pharm. 1993; 12: 829-845.
  • 10
    Elting LS, Rubenstein EB, Rolston KV, et al. Outcomes of bacteremia in patients with cancer and neutropenia: observations from 2 decades of epidemiological and clinical trials. Clin Infect Dis. 1997; 25: 247-259.
  • 11
    Schwenkglenks M, Jackisch C, Constenla M, et al. Neutropenic event risk and impaired chemotherapy delivery in 6 European audits of breast cancer treatment. Support Care Cancer. 2006; 14: 901-909.
  • 12
    Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw. 2008; 6: 122-174.
  • 13
    Chang J. Chemotherapy dose reduction and delay in clinical practice. Evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000; 36( suppl 1): S11-S14.
  • 14
    Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer. 1971; 28: 1479-1499.
  • 15
    Bonadonna G, Moliterni A, Zambetti M, et al. 30 Years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study [serial online]. BMJ. 2005; 330: 217.
  • 16
    Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981; 304: 10-15.
  • 17
    Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332: 901-906.
  • 18
    Bonneterre J, Roche H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol. 2005; 23: 2686-2693.
  • 19
    Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998; 90: 1205-1211.
  • 20
    Kwak LW, Halpern J, Olshen RA, et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990; 8: 963-977.
  • 21
    Pettengell R, Gurney H, Radford JA, et al. Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood. 1992; 80: 1430-1436.
  • 22
    Kuderer NM, Dale DC, Crawford J, et al. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25: 3158-3167.
  • 23
    Eldar-Lissai A, Cosler LE, Culakova E, et al. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 2008; 11: 172-179.
  • 24
    Kern WV. Risk assessment and treatment of low-risk patients with febrile neutropenia. Clin Infect Dis. 2006; 42: 533-540.
  • 25
    Rosenbaum P, Rubin D. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Amer Statist. 1985; 39: 33-38.
  • 26
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 27
    National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: Prevention and Treatment of Cancer-Related Infections. Fort Washington, Pa: National Comprehensive Cancer Network; 2007.
  • 28
    Weycker D, Malin J, Edelsberg J, Glass A, Gokhale M, Oster G. Cost of neutropenic complications of chemotherapy. Ann Oncol. 2008; 19: 454-460.
  • 29
    Chen-Hardee S, Chrischilles EA, Voelker MD, et al. Population-based assessment of hospitalizations for neutropenia from chemotherapy in older adults with non-Hodgkin's lymphoma (United States). Cancer Causes Control. 2006; 17: 647-654.